The influence of metyrapone on the synthesis and release of prostaglandins from the pregnant rat uterus in vitro.
1 Metyrapone (150 mg/kg, s.c. or i.p.) an inhibitor of corticosteroid biosynthesis, significantly reduced the release of prostaglandins of the F-type from isolated preparations of pregnant rat uteri in vitro, on day 22 - the expected day of delivery. 2 Metyrapone and indomethacin administered in vitro both inhibited the conversion of 14C-arachidonic acid to prostaglandin E2 by homogenates of day 22 pregnant rat uteri. Metyrapone was approximately 150 times less potent than indomethacin. Although indomethacin also inhibited prostaglandin F2alpha production, metyrapone stimulated synthesis of this prostaglandin. The differential inhibition of prostaglandin synthesis by metyrapone may reflect sensitivity of the inhibitor to changes in experimental conditions. 3 Inhibition of prostaglandin synthesis may explain the effects of metyrapone on parturition in the rat.
D000818:Animals; D005260:Female; D007213:Indomethacin / Q000494:pharmacology; D008797:Metyrapone / Q000494:pharmacology*; D011247:Pregnancy; D011270:Pregnancy, Animal; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D011458:Prostaglandins E / Q000096:biosynthesis / Q000378:metabolism*; D011460:Prostaglandins F / Q000096:biosynthesis / Q000378:metabolism*; D051381:Rats; D014590:Uterine Contraction / Q000187:drug effects; D014599:Uterus / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*
D011458:Prostaglandins E; D011460:Prostaglandins F; D011451:Prostaglandin-Endoperoxide Synthases; D007213:Indomethacin; D008797:Metyrapone